about
Adenosine and prostaglandin E2 cooperate in the suppression of immune responses mediated by adaptive regulatory T cellsCyclooxygenase- and lipoxygenase-mediated DNA damage.Stromal, rather than epithelial cyclooxygenase-2 (COX-2) expression is associated with overall survival of breast cancer patients.Immune profiling and cancer post transplantationA systematic review to establish the frequency of cyclooxygenase-2 expression in normal breast epithelium, ductal carcinoma in situ, microinvasive carcinoma of the breast and invasive breast cancerRottlerin enhances IL-1β-induced COX-2 expression through sustained p38 MAPK activation in MDA-MB-231 human breast cancer cellsCyclooxygenase-2 expression as a predictor of outcome in colorectal carcinoma.Association between 8473T>C polymorphism in the cyclooxygenase-2 gene and the risk of nasopharyngeal carcinoma.What are cyclooxygenases and lipoxygenases doing in the driver's seat of carcinogenesis?A mechanism underlying the effects of polyunsaturated fatty acids on breast cancer.Immune suppression in tumors as a surmountable obstacle to clinical efficacy of cancer vaccinesCanine mammary tumours, an overview.Stromal biomarkers in breast cancer development and progression.The obesity-inflammation-eicosanoid axis in breast cancer.Targeted chiral analysis of bioactive arachidonic Acid metabolites using liquid-chromatography-mass spectrometry.Secretion of IL-1β from imatinib-resistant chronic myeloid leukemia cells contributes to BCR-ABL mutation-independent imatinib resistance.Metabolic Hallmarks of Tumor and Immune Cells in the Tumor MicroenvironmentINCORPORATING BIOLOGICAL INFORMATION INTO LINEAR MODELS: A BAYESIAN APPROACH TO THE SELECTION OF PATHWAYS AND GENES.Understanding and Targeting the Eukaryotic Translation Initiation Factor eIF4E in Head and Neck Cancer.COX-2 expression in human breast carcinomas: correlation with clinicopathological features and prognostic molecular markers.Aspirin use and breast cancer risk: a meta-analysis and meta-regression of observational studies from 2001 to 2005.Impact of cyclooxygenase-2 over-expression on the prognosis of colorectal cancer patients. An experience from Western Saudi Arabia
P2860
Q34107172-545293A6-844C-430D-A2F5-E40A54D040FDQ34225293-CD938B60-B253-485F-BFEB-E22BAA0D9047Q34316720-4186FE26-1B0D-43A6-B69A-973F49CED71EQ35050810-3AA8D438-A12C-4ADC-AA15-2C2CD4E1CEE4Q35108403-1D169F13-CAEA-4AF1-978E-6C874ACC2D08Q35667259-B471176F-27D9-4243-B633-9087F70E7D25Q35904309-EE9A7388-E05D-4D26-A2B6-DFD2B1200AA3Q35919516-94A711A0-F2A4-4F64-9C65-F5FD6CDBB57CQ36572139-7D41BDF4-0B5C-4B98-BAA7-147F2AC6FB25Q36613639-F67F8B35-6052-463E-9040-E2EB53DCE810Q37137360-0D73C009-FFB5-4648-BFF8-A5ABF5EEE465Q37885436-1E72CC4B-5A8F-4535-8BD7-C115026C4E9FQ38017601-AF1B8E5C-5994-4B9D-8373-6CD3D9B73E37Q38156366-B5815FF2-6387-4D18-9DFE-F169BAD1B4DEQ38222606-B7D4ADD4-0922-409E-8A41-932EFF411263Q38797633-7B40822B-8440-4404-B27B-1A4FB04D357BQ39197674-E72072E9-5494-44A5-AF44-343C05AEE9E9Q40614440-F00255DE-2AE6-4F7E-A52C-20FE0618B2C7Q42946802-4444E761-E52C-4B5A-81EB-2C640C2A3E5FQ43035066-EF0A44FB-6201-4C09-84B8-3C1309C79FCDQ44231964-FF04FC4C-05B9-4CB9-B838-178CBFF8C9ACQ58804016-1A3AFFCB-5D8F-4DF4-9AC9-8AAF06B35D64
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Prognostic impact of cyclooxygenase-2 in breast cancer.
@ast
Prognostic impact of cyclooxygenase-2 in breast cancer.
@en
type
label
Prognostic impact of cyclooxygenase-2 in breast cancer.
@ast
Prognostic impact of cyclooxygenase-2 in breast cancer.
@en
prefLabel
Prognostic impact of cyclooxygenase-2 in breast cancer.
@ast
Prognostic impact of cyclooxygenase-2 in breast cancer.
@en
P356
P1476
Prognostic impact of cyclooxygenase-2 in breast cancer
@en
P2093
Klaus-Jürgen Winzer
Steffen Hauptmann
P304
P356
10.3816/CBC.2004.N.006
P407
P577
2004-02-01T00:00:00Z